DRKY - ETF AI Analysis

Top Page

VistaShares Target 15 DRUKMacro Distribution ETF (DRKY)

Rating:68Neutral

Price Target:―

The overall rating of the DRKY ETF suggests it is a moderately strong investment option with a mix of promising and challenging holdings. TSMC stands out as a key contributor to the fund’s rating due to its strong financial performance and strategic focus on advanced technologies, which position it well for future growth. However, holdings like Insmed and Teva slightly weigh down the rating due to ongoing financial challenges and valuation concerns. The ETF's concentration in a few high-weighted holdings may pose a risk if these companies face significant setbacks.

Positive Factors

Strong Top Holdings

Several of the largest positions, such as Natera and Insmed, have delivered strong year-to-date gains, supporting the ETF’s overall performance.

Sector Focus on Health Care

With significant exposure to the health care sector, the ETF benefits from a defensive industry that often performs well in various market conditions.

Steady Year-to-Date Performance

The ETF has shown positive year-to-date performance, indicating resilience in its portfolio despite broader market challenges.

Negative Factors

High Expense Ratio

The ETF charges a relatively high expense ratio, which can eat into investor returns over time compared to lower-cost alternatives.

Over-Concentration in Health Care

With over 40% of the portfolio allocated to health care, the ETF is heavily reliant on the performance of a single sector.

Limited Geographic Diversification

The ETF is overwhelmingly focused on U.S. companies, offering minimal exposure to international markets and reducing global diversification.

DRKY vs. SPDR S&P 500 ETF (SPY)

AUM4.99M

RegionNorth America

Expense Ratio0.95%

Beta0.59

IssuerVistaShares

Inception DateOct 08, 2025

Dividend Yield2.32%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume8,590

30 Day Avg. Volume9,028

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

26.17

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering21

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DRKY Summary

VistaShares Target 15 DRUKMacro Distribution ETF (Ticker: DRKY) is an actively managed fund that focuses on the U.S. equity market across all company sizes and styles. It aims to provide diversified exposure while generating income for investors. The ETF is influenced by the investment strategies of Stanley Druckenmiller’s Duquesne Family Office, offering access to high-level financial insights. Some of its top holdings include Natera, a healthcare company, and Warner Bros, a well-known entertainment brand. This ETF might appeal to investors looking for growth and income through a broad market approach. However, it carries risks like market fluctuations and heavy exposure to healthcare stocks, which could impact performance.

How much will it cost me?The expense ratio for the VistaShares Target 15 DRUKMacro Distribution ETF (Ticker: DRKY) is 0.95%, meaning you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using sophisticated strategies and insights from the Duquesne Family Office to maximize income and returns.

What would affect this ETF?The DRKY ETF, with its strong focus on U.S. equities and significant exposure to healthcare and technology sectors, could benefit from advancements in medical innovation and tech growth, especially if economic conditions remain favorable for these industries. However, its reliance on derivative strategies and concentration in specific sectors may pose risks during periods of market volatility or regulatory changes affecting healthcare and technology. Broader economic factors, such as interest rate hikes or a slowdown in consumer spending, could also impact the ETF's performance negatively.

DRKY Top 10 Holdings

The DRKY ETF leans heavily into health care, with Natera leading the charge thanks to rising momentum and strong earnings, while Teva Pharmaceutical adds steady gains despite ongoing financial challenges. Insmed is another health care name showing mixed performance, with bullish trends tempered by cash flow concerns. Technology stocks like TSMC and Coherent Corp provide a growth-oriented edge, though TSMC’s slight dip and valuation worries hint at caution. Overall, the fund’s concentration in health care and technology positions it for growth, but a few lagging names like Entegris are holding back broader performance.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NTRA	Natera	18.66%	$931.33K	$32.33B	45.85%	73 Outperform
TEVA	Teva Pharmaceutical	13.99%	$698.22K	$35.92B	40.05%	63 Neutral
INSM	Insmed	10.50%	$524.28K	$37.94B	155.54%	43 Neutral
TSM	TSMC	7.82%	$390.23K	$1.25T	50.20%	81 Outperform
CPNG	Coupang	5.68%	$283.36K	$44.33B	7.77%	60 Neutral
WWD	Woodward	5.66%	$282.48K	$18.64B	83.26%	79 Outperform
MELI	Mercadolibre	4.48%	$223.80K	$101.68B	16.24%	77 Outperform
DOCU	DocuSign	4.22%	$210.59K	$14.01B	-24.76%	71 Outperform
FIGR	Figure Technology Solutions, Inc. Class A	3.54%	$176.80K	$9.43B	―	68 Neutral
STUB	StubHub Holdings Incorporation Class A	3.36%	$167.62K	$4.59B	―	59 Neutral

DRKY Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

21.13

Positive

100DMA

200DMA

Market Momentum

MACD

0.27

Positive

RSI

63.41

Neutral

STOCH

88.43

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DRKY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 21.98, equal to the 50-day MA of 21.13, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 63.41 is Neutral, neither overbought nor oversold. The STOCH value of 88.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRKY.

DRKY Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DRKY	―	―	$4.99M	0.95%	―
BAMD	―	―	$98.75M	0.89%	―
STNC	―	―	$94.56M	0.85%	―
RFDA	―	―	$85.37M	0.52%	―
STOX	―	―	$82.56M	0.70%	―
LSAT	―	―	$73.91M	0.99%	―

Performance Comparison

DRKY

VistaShares Target 15 DRUKMacro Distribution ETF

22.24

2.53

12.84%

BAMD

Brookstone Dividend Stock ETF

―

STNC

Stance Equity ESG Large Cap Core ETF

―

RFDA

RiverFront Dynamic US Dividend Advantage ETF

―

STOX

Horizon Core Equity ETF

―

LSAT

Leadershares Alphafactor Tactical Focused ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents